Receives $1.249m R&D Tax Refund
The refund is from Anatara's 2017-2018 research activities and reflects a period of significant investment in the Company's lead human product, a Gastrointestinal ReProgramming (GaRP) dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).
Anatara's CEO, Mr Steven Lydeamore said, "The Company's emphasis on R&D activities during the 2017-2018 period was key to Anatara's transition into human health, following the successful licencing of our lead animal product, Detach, to Zoetis Inc in May 2018. The R&D tax incentive scheme provides an important source of non-dilutive funding and enables the Company to remain well funded as we progress the development and commercialisation of our GaRP product, while also expanding our human product pipeline."
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd